PF-00547659 is an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease (IBD). The biologic is designed to directly target a gastrointestinal (GI) endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1), that binds to the α4β7 integrin on lymphocytes.
Shire has rolled out their long-acting ADHD (attention deficit hyperactivity disorder) drug Intuniv nationwide. In doing so the treatment options for patients aged six to 17 years old in whom stimulant medicines are not suitable or are ineffective has been extended.
Shire plc and Baxalta Incorporated announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta. The value of the offer, as of Shire’s January 8, 2016 closing ADS price, represents a premium of approximately 37.5% to Baxalta’s unaffected share price on August 3, 2015, the
The US Food and Drug Administration (FDA) have ruled against Shire in a clash surrounding generic copies of their ADHD medication, Adderall XR, by approving a cheap version of the drug from Watson’s Actavis division. The verdict is a setback to Shire’s near-term earnings and shares, with the drug maker’s shares falling 12.4% to £17.23
